Ariad Pharmaceuticals, Inc. (ARIA) Provides Update on Important Progress Being Made in R&D and Commercial Initiatives  
4/4/2013 11:55:15 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today provided an update on its progress over the past several weeks with both the commercial launch of Iclusig™ (ponatinib) in the United States and the clinical development programs for Iclusig and AP26113. We are providing this update to further clarify our recent news announcements and to respond to investor questions.